



* 1. Consultancy
     + Consultancy to a company shall mean: any activity where the board member provides advice (including training on a one to one basis) to a company regardless of contractual arrangements or any form of remuneration.
  2. Consultancy/advisory role on patient-related activities in the last year
     + The board member provides advice or participates in consultations regarding patient-related activities of a company that are strictly non-commercial (e.g. educational seminars, preparation and participation in patient meetings/trainings, development of non-product patient specific materials, participation in trainings of a company staff on patient-centricity etc.)

Public Declaration of Interests The European Patients’ Forum Board Members

Public Declaration of Interests

I,

# Name: Isabel Proaño Gómez

**Organisation**: European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)

# Country: Belgium

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in healthcare industries are those listed below:

Please indication N/A (Not applicable) as appropriate

2.1 Employment in the healthcare industry

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Job title** |
| N/A |  |  |

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Subject Matter** |
| N/A |  |  |

Strategic

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Subject Matter** |
| N/A |  |  |

Advisory Role

Strategic advisory role for a company shall mean: any activity where the board members participating (with a right to vote/influence the outputs) in a(n) (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the (future) strategy, direction and development activities of a healthcare company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration.

|  |  |  |  |
| --- | --- | --- | --- |
| **Period** | **Company** | **Product** | **Therapeutic Indication** |
| N/A |  |  |  |

* 1. Financial Interests

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Subject Matter** |
| N/A |  |  |

* 1. Principal Investigator

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Subject Matter** |
| N/A |  |  |

* 1. Investigator

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Subject Matter** |
| N/A |  |  |

* 1. Grant / Funding to Organisation /Institution in 2021 (This is the organisation which nominated you to become a member of EPF)

|  |  |
| --- | --- |
| **Company** | **Subject Matter and amount** |
| Abbvie | EUR 30,000 (operating programme)  EUR 41,433 (Atopic Eczema Consensus project) |
| Aimmune | EUR 30,000 (operating programme) |
| Astra Zeneca | EUR 30,000 (operating programme)  EUR 29,920 (BREATHE Coalition project)  EUR 38,225 (Capacity Building project)  EUR 76,371 (DIG\_IT project) |
| Boehringer Ingelheim | EUR 30,000 (operating programme)  29,920 (BREATHE Coalition project) |
| Chiesi | EUR 30,000 (operating programme)  EUR 29,920 (BREATHE Coalition project)  EUR 25,483 (Capacity Building project)  EUR 76,371 (DIG\_IT project)  EUR 15,106 (Interest Group on Allergy and Asthma project) |
| DBV Technologies | EUR 30,000 (operating programme) |
| GSK | EUR 30,000 (operating programme)  EUR 29,920 (BREATHE Coalition project)  EUR 15,106 (Interest Group on Allergy and Asthma project) |
| LEO Pharma | EUR 30,000 (operating programme)  EUR 41,433 (Atopic Eczema Consensus project) |
| MSD | EUR 30,000 (operating programme)  EUR 76,371 (DIG\_IT project) |
| Novartis | EUR 30,000 (operating programme)  EUR 25,483 (Capacity Building project) |
| OM Vifor Pharma | EUR 30,000 (operating programme)  EUR 76,371 (DIG\_IT project) |
| Pfizer | EUR 30,000 (operating programme) |
| Roche | EUR 30,000 (operating programme)  EUR 29,920 (BREATHE Coalition project)  EUR 76,371 (DIG\_IT project) |
| Sanofi Genzyme /  Regeneron | EUR 60,000 (operating programme)  EUR 41,433 (Atopic Eczema Consensus project)  EUR 15,106 (Interest Group on Allergy and Asthma project) |

* 1. Close Family Member Interest

|  |  |  |
| --- | --- | --- |
| **Period** | **Company** | **Interest** |
| N/A |  |  |

* 1. Any Other Interests or Facts

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EPF website.

|  |  |
| --- | --- |
| **Full Name** | Isabel Proaño Gómez |
| **Date** | 10/05/2022 |